Role of Erbitux plus a combination of CPT-11/5-fluorouracil/leucovorin/oxaliplatin as neoadjuvant chemotherapy in patients with colorectal liver metastases.

Trial Profile

Role of Erbitux plus a combination of CPT-11/5-fluorouracil/leucovorin/oxaliplatin as neoadjuvant chemotherapy in patients with colorectal liver metastases.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 May 2011

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Irinotecan; Levofolinic acid; Oxaliplatin
  • Indications Colorectal cancer; Liver metastases
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top